ITGA5
Integrin alpha-5
As of the edition of 20 October 2026, ITGA5 (integrin alpha-5, UniProt P08648) has 3 drugs tested at it and 5 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08648
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 16
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Hormones; Lungs and airways; Digestive system; Skin and connective tissue; Eye
- Registered trials of its drugs
- 13
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Volociximab | Went quiet | Phase 2 | none listed |
| ATN-161 | Went quiet | Phase 2 | none listed |
| PF-04605412 | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Total on the list | 5 |
The other 2 companies at ITGA5
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at ITGA5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.